• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Nanoparticles could improve efficacy of cancer immunotherapy

April 4, 2017 By Sarah Faulkner

Study: Nanoparticles could improve cancer immunotherapy drugsResearchers from the University of North Carolina have discovered that they can potentially improve cancer immunotherapy drugs by binding 2 compounds to a single nanoparticle. The team’s work was presented this week at the annual meeting of the American Association for Cancer Research.

“Our data shows that 2 compounds on a single nanoparticle will make immunotherapy treatments even more effective,” senior author Dr. Andrew Wang said in prepared remarks.

The team evaluated nanoparticles as a delivery vehicle for checkpoint inhibitors and T-cell agonists in a preclinical model.

T-cells, a type of immune cell, have “checkpoints” that act to ensure the T-cells don’t attack things inside the body that should be left alone. A checkpoint inhibitor turns off the checkpoint, which enables T-cells to detect and attack cancer cells.

But in some cases, a checkpoint inhibitor may not be enough, the researchers said. So the team combined the checkpoint inhibitor with a T-cell agonist, which is designed to trigger T-cell activation.

“Some agents help T-cells with proliferation and survival, while others overcome the T-cells’ self-regulation and inhibition,” 1st author Yu Mi said. “Nanoparticles provide us with a tool to co-deliver different agents to T-cells so they will be activated by both of the agents at the same time.”

In preclinical models, the team reported better stimulation of T-cells and better survival rates compared to a control.

“We found that the therapeutic effect of nanoparticles is far better than the mixture of free agents,” Mi said.

Filed Under: Featured, Immunotherapy, Oncology, Research & Development, Wall Street Beat Tagged With: University of North Carolina

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS